Biostage is moving closer to human trials of its esophagus regeneration technology, anticipated to take place in 2017, on the back of an additional $5 million in funding gained through a stock offer.
http://www.wbjournal.com/article/20160622/NEWS01/160629974/1002
Biostage closer to human testing on momentum of $5M stock offering